-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Severely ill patients with new coronary disease can lead to long-term mental confusion
Severely ill patients with new coronary disease can lead to long-term mental confusionSource: BMJ Open
Source: BMJ Open Source: BMJ OpenOn September 17, a study published in the "British Medical Journal Open Edition" (BMJ Open) found that severely ill patients with new coronary disease will experience persistent mental confusion, which is manifested by confusion and decreased awareness of the surrounding environment.
Researchers analyzed 148 severely ill patients with new coronary disease.
mRNA vaccines can protect non-human primates from the new coronavirus
mRNA vaccines can protect non-human primates from the new coronavirusSource: Science
Source: Science Source: ScienceOn September 17, a study published in Science showed that the humoral immune response induced by the mRNA-1273 vaccine can provide non-human primates (NHPs) with protection against the new coronavirus
Researchers vaccinate NHPs with 0.
In addition, injecting immunoglobulin G induced by the mRNA-1273 vaccine into young hamsters is sufficient to provide protection against the new coronavirus
Laos finds the closest coronavirus to the new coronavirus so far
Laos finds the closest coronavirus to the new coronavirus so farIn a work published on the preprint platform Research Square on September 18th, researchers discovered in northern Laos that the bat coronavirus, which is the closest to the new coronavirus so far, shares key features with the new coronavirus, and may have evolved with the new coronavirus Relationship
Studies have pointed out that the RBD of the coronavirus found in bats in Laos is only one or two amino acids apart from the RBD of the new coronavirus, and it can strongly bind to the human ACE2 receptor and infect human cells
The researchers made it clear that the evolutionary history of the new coronavirus is more complicated than expected, and the RaTG13 virus found in China cannot now be considered the nearest ancestor of the new coronavirus
The RaTG13 virus found in China cannot now be considered the nearest ancestor of the new coronavirus
Pfizer vaccine is safe and effective for children aged 5 to 11 years
On September 20, Pfizer and BioNTech jointly announced that their co-developed new crown mRNA vaccine COMIRNATY? It shows good safety and strong neutralizing antibody response in children aged 5 to 11 years
A total of 2268 children between 5 and 11 years old received a dose regimen of 10 μg each time and 21 days apart
New coronavirus protease inhibitory target can block infection
New coronavirus protease inhibitory target can block infectionSource: Nature Communications
Source: Nature Communications Source: Nature CommunicationsOn September 21, in a work published in Nature Communications, researchers used mass spectrometry to study the protein cleavage event during the new coronavirus infection, and explained the process of viral protease attacking host cells and the related use The way drugs prevent viruses from replicating in cell culture
The research team found previously unknown cleavage sites in a variety of viral proteins, including the main antigen proteins S and N, which are the main targets of vaccine and antibody testing
carolacton can effectively inhibit the replication of the new coronavirus
carolacton can effectively inhibit the replication of the new coronavirusSource: PNAS
Source: PNAS Source: PNASOn September 21, published in the Proceedings of the National Academy of Sciences (PNAS), a series of virus-dependent host genes were identified through functional screening of the bat genome, and it was finally found that the host protein MTHFD1 inhibitor carolacton is effective Inhibit the replication of the new coronavirus
The research team conducted a systematic and comprehensive screening of more than 20,000 genes in bat cells and identified dozens of key bat genes on which virus replication depends
It was further discovered that a variety of RNA viruses are very sensitive to the deletion of MTHFD1, and the inhibitor carolacton of MTHFD1 has a very strong inhibitory effect on the replication of related viruses.
The new coronavirus discovered at the beginning of the infection epidemic is not enough to completely prevent the mutant strain
The new coronavirus discovered at the beginning of the infection epidemic is not enough to completely prevent the mutant strainSource: Science Translational Medicine
Source: Science Translational Medicine Source: Science Translational MedicineOn September 21, a study published in "Science Translational Medicine" (Science Translational Medicine) showed that for the alpha and beta variants of the new coronavirus, the new coronavirus strain (known as WA1/2020) found at the beginning of the epidemic The natural immunity caused by virus strains leads to partial but incomplete protection.
This discovery has important implications for vaccination and public health strategies
.
The results of the study show that the natural immunity of WA1/2020 provides strong protection, enough to prevent animals from being infected by WA1/2020 again, while the alpha mutant strain caused slightly more "breakthrough viruses", which can be recovered from the respiratory tract of monkeys after re-attack.
A certain concentration of viral nucleic acid was detected in the virus, indicating that the natural immunity after WA1/2020 infection has only a partial protective effect
.
For the beta mutants that mutated more in key parts of the virus, monkeys infected by WA1/2020 also did not get complete protection, and the detectable virus concentration was higher
.
The U.
S.
New Crown "Patient Zero" has a high probability of appearing around September 2019
S.
New Crown "Patient Zero" has a high probability of appearing around September 2019
Source: ChinaXiv
Source: ChinaXiv Source: ChinaXivOn September 22, in a study published on ChinaXiv, a pre-release platform for scientific and technological papers of the Chinese Academy of Sciences, the traceability results obtained based on the new big data analysis method showed that the United States' new crown "patient zero" has a high probability of appearing around September 2019 Among them, the earliest first case of infection has a 50% probability of occurring in Rhode Island, and the date is April 26, 2019, which is much earlier than the official US official date of the first confirmed case in the United States on January 20, 2020
.
Based on published data and based on infectious disease models and statistical methods, researchers established an optimized model to infer the origin time of the epidemic in some states in the United States, Wuhan, Zhejiang and other places in China.
If the initial detection of the epidemic in other countries or regions is The data is relatively accurate, and this method can be used to infer the origin time of the epidemic, and the infection time of the first case and several cases can be calculated in the sense of a given probability
.
The results of phase II/III phases of domestically produced high-protective vaccines are released, and their protective efficacy against delta mutant strains is 79%
The results of phase II/III phases of domestically produced high-protective vaccines are released, and their protective efficacy against delta mutant strains is 79%Source: Clover Biopharmaceuticals
Source: Clover Biopharmaceuticals Source: Clover BiopharmaceuticalsOn September 22, China Clover Biopharmaceutical Co.
, Ltd.
and the Epidemic Prevention Innovation Alliance (CEPI) jointly announced that the recombinant protein new crown vaccine candidate SCB-2019 (CpG1018/aluminum adjuvant) used in the clover biological combined adjuvant is critical in the world II / Phase III clinical trials ("SPECTRA") reached the primary and secondary endpoints of protective efficacy
.
The new crown virus strains observed in the analysis of the test results are all variant strains, showing the protective efficacy of the vaccine against the variant strains
.
The results showed that the protective effect of preventing any severity of new coronary pneumonia caused by any strain was 67.
2%, successfully reaching the primary endpoint
.
The protective effects against the three most important strains were: 91.
8% of the gamma mutant, 78.
7% of the delta mutant, and 58.
6% of the Mu strain
.
Vaccines can significantly reduce the risk of new coronary pneumonia in previously infected people, and are safe.
Compared with placebo, there is no significant difference in the incidence of systemic adverse events
.
Nanobodies derived from llamas have the potential to prevent new crowns
Nanobodies derived from llamas have the potential to prevent new crownsSource: Nature Communications
Source: Nature Communications Source: Nature CommunicationsIn a work published in Nature Communications on September 22, researchers have developed 4 unique nano-antibodies derived from llamas that have the potential to prevent new crowns
.
In mouse trials, one of the vaccines was not only injectable, but also showed good preventive effects through nasal inhalation
.
Researchers injected the SARS-CoV-2 spike protein into the llama to trigger its immune response, thereby obtaining a series of single-domain heavy chain antibodies (VHH), and screening four types of VHH, C1, H3, C5, and F2
.
The results show that H3, C5, and F2 can effectively neutralize the original strain of the new crown virus and the alpha mutant, while the nanobody that is active against the beta mutant is only C1
.
In addition, C5 performed best overall in vitro, and was able to significantly reduce the symptoms of the disease in infected mice, and the viral load in the lungs and respiratory tracts was also lower after 7 days
.
.
In addition, C5 performed best overall in vitro, and was able to significantly reduce the symptoms of the disease in infected mice, and the viral load in the lungs and respiratory tracts was also lower after 7 days
.
The preventive efficacy of the recombinant nanoparticle vaccine is 89.
7%
7% The preventive efficacy of the recombinant nanoparticle vaccine is 89.
7%
Source: NEJM
Source: NEJM Source: NEJMOn September 23, a study published in the New England Journal of Medicine (NEJM) showed that after adult participants were vaccinated with a two-dose regimen of the recombinant nanoparticle vaccine NVX-CoV2373, the vaccine's effectiveness against new coronavirus infection was 89.
7%.
, And has a high preventive effect on Alpha mutant strains
.
A total of 15,187 participants underwent randomization, and 14,039 were included in the population meeting the efficacy of the program, of which 27.
9% of the participants were ≥65 years of age, and 44.
6% had comorbidities
.
Ten participants in the vaccine group and 96 participants in the placebo group developed infections that developed at least 7 days after receiving the second injection.
The vaccine efficacy was 89.
7%.
None of the 10 patients in the vaccine group were hospitalized or died
.
This trial reported 5 severe infections, all of which occurred in the placebo group
.
Analysis shows that the vaccine has a preventive effect of 86.
3% against alpha variant strains and 96.
4% against other variant strains
.
The reactogenicity is generally mild and transient, and the incidence of serious adverse events in the two groups is relatively low and similar
.
3% against alpha mutant strains and 96.
4% against other mutant strains
.
The immunological features of asymptomatic infections were discovered
The immunological features of asymptomatic infections were discoveredSource: Cell Research
Source: Cell Research Source: Cell ResearchOn September 24, in a work published in Cell Research, researchers used Olink detection technology that integrates mass spectrometry flow cytometry, transcriptome sequencing and plasma microproteins to reveal for the first time the distinction between persistent asymptomatic infections And the main immunological characteristics of asymptomatic infections during the incubation period
.
The study combined its clinical characteristics and discovered the key immune mechanism that affects the progress of the disease in the silent infection stage (SSIS) of the new crown infection in different directions.
On this basis, the markers that can be achieved by simple ELISA detection methods were identified, and The feasibility was verified in another cohort, and it provided a theoretical basis for early identification of asymptomatic infections in the incubation period in clinical work, and timely intervention and blocking of their progress at an earlier stage to provide a theoretical basis for confirmed patients
.
Leave a message here
